Immunotherapy for Glioma: A compartmental framework for resistance and rational combination design
- 1Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA
- 2Corresponding author.
Abstract
Diffuse gliomas remain among the least responsive solid tumors to immunotherapy despite a compelling rationale for immune surveillance of infiltrative disease. The clinical record—negative phase III checkpoint blockade trials, limited durability of single-antigen vaccines, and impressive but transient responses to adoptive cellular therapy—suggests that failure is rarely attributable to a single mechanism. We propose that glioma immunotherapy resistance is best understood as a compartmental problem. Effective antitumor immunity must traverse a sequence of spatially and functionally distinct compartments: antigen generation and drainage; T-cell priming in deep cervical lymph nodes, cranial bone marrow, or tertiary lymphoid structures; trafficking through vascular and stromal gateways; and effector persistence within a myeloid-rich, metabolically stressed tumor microenvironment. Each therapeutic class acts with a different compartmental center of gravity. Vaccines amplify priming but do not guarantee tumor access or persistence; checkpoint inhibitors require a pre-existing or newly generated tumor-reactive T-cell pool; adoptive cellular therapies bypass priming but remain vulnerable to antigen heterogeneity and local suppression; and oncolytic or innate immune agonists can create in situ inflammatory signals but require compatible trafficking and effector niches. This framework explains why monotherapies have generally underperformed and why effective combinations must be designed to bridge specific blocked compartments rather than simply intensify immune stimulation. It also highlights the importance of tumor state: treatment-naive and treatment-remodeled gliomas may have different dominant immune barriers. Future trials should pair mechanism-matched combinations with biomarkers that report on priming, trafficking, and effector competence.
Related
- Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer
- EZH2 at the epigenetic–immune interface: a dual-axis framework for tumor immune evasion and precision combination immunotherapy
- Exploring the potential role of PD-L2 in primary melanoma immunotherapy resistance: a hypothesis-driven dual-ligand framework
- Cancer therapy resistance converges on immune evasion: a unified framework from immunotherapy to targeted, endocrine, and DNA repair pathways
- BNCT Triggers Immunogenic Cell Death in B16 Melanoma Without Accompanying T-Cell Infiltration--Implications for Combination Immunotherapy
BibTeX
@article{nageeb2026immunotherapy,
title = {{Immunotherapy for Glioma: A compartmental framework for resistance and rational combination design}},
author = {George Nageeb and Joseph H. Ha and Justin Liu and Matthew Adam Sjoholm and Michael Lim},
journal = {Neurotherapeutics},
year = {2026},
month = oct,
doi = {10.1016/j.neurot.2026.e01035},
url = {https://doi.org/10.1016/j.neurot.2026.e01035},
note = {CC BY},
}
RIS
TY - JOUR
TI - Immunotherapy for Glioma: A compartmental framework for resistance and rational combination design
AU - George Nageeb
AU - Joseph H. Ha
AU - Justin Liu
AU - Matthew Adam Sjoholm
AU - Michael Lim
PY - 2026
DA - 2026/10/24
JO - Neurotherapeutics
DO - 10.1016/j.neurot.2026.e01035
UR - https://doi.org/10.1016/j.neurot.2026.e01035
AB - Diffuse gliomas remain among the least responsive solid tumors to immunotherapy despite a compelling rationale for immune surveillance of infiltrative disease. The clinical record—negative phase III checkpoint blockade trials, limited durability of single-antigen vaccines, and impressive but transient responses to adoptive cellular therapy—suggests that failure is rarely attributable to a single mechanism. We propose that glioma immunotherapy resistance is best understood as a compartmental problem. Effective antitumor immunity must traverse a sequence of spatially and functionally distinct compartments: antigen generation and drainage; T-cell priming in deep cervical lymph nodes, cranial bone marrow, or tertiary lymphoid structures; trafficking through vascular and stromal gateways; and effector persistence within a myeloid-rich, metabolically stressed tumor microenvironment. Each therapeutic class acts with a different compartmental center of gravity. Vaccines amplify priming but do not guarantee tumor access or persistence; checkpoint inhibitors require a pre-existing or newly generated tumor-reactive T-cell pool; adoptive cellular therapies bypass priming but remain vulnerable to antigen heterogeneity and local suppression; and oncolytic or innate immune agonists can create in situ inflammatory signals but require compatible trafficking and effector niches. This framework explains why monotherapies have generally underperformed and why effective combinations must be designed to bridge specific blocked compartments rather than simply intensify immune stimulation. It also highlights the importance of tumor state: treatment-naive and treatment-remodeled gliomas may have different dominant immune barriers. Future trials should pair mechanism-matched combinations with biomarkers that report on priming, trafficking, and effector competence.
SN - 1878-7479
SN - 1933-7213
ER -